We develop next generation genetic therapies using our Fusogenix nucleic acid delivery platform.
Dr. Lewis is the Frank and Carla Sojonky Chair in Prostate Cancer Research at the University of Alberta in Edmonton, Alberta. A scientist and serial entrepreneur, his research interests lie in the areas of nanotechnology and imaging as they relate to the development of novel treatments for chronic diseases such as aging and cancer. He has pioneered the use of intravital imaging to discover key therapeutic targets in cancer.READ FULL BIO
Dr. Raturi leads the development of the Entos Fusogenix platform. He has considerable experience in the development and characterization of pharmaceutics and biologics, with more than 6 years of industry experience in various roles. Dr. Raturi trained at The Scripps Research Institute in La Jolla, CA, and holds a Ph.D. in biochemistry from the University of Windsor.READ FULL BIO
Specializing in Life Sciences, Dr Coros has a passion for starting and growing companies. As the CEO of the Delta Genomics Centre, Dr Coros built a national, biobanking, genotyping, and sequencing company and he is also the co-founder of Helios Genomics a metagenomics company specializing in the Energy sector.READ FULL BIO
With many years of experience studying viral fusion proteins as a Professor and Killam Chair at Dalhousie University, Dr. Roy Duncan is well known and respected internationally as an expert in the field.READ FULL BIO
Dr. Andries Zijlstra received his Ph.D. in Genetics and Cell Biology from Washington State University and completed his postdoctoral research at the Scripps Research Institute of California. He is currently Associate Professor of Pathology and Cancer Biology at Vanderbilt University Medical Center.READ FULL BIO